Commentary:

Highlight of 2024/2025 interim report:

EC Healthcare's 2024 half-yearly report, for the six months ended September 30, 2024, shows a revenue of HK$2,063 million, down 2.8 % year-on-year, but with improved profitability.

EBITDA increased by 18.8% to HK$248 million, and net profit was HK$40.3 million, with earnings per share up 100% to 1.2 HK cents.

The company declared an interim dividend of 1.0 HK cents per share.

The interim report indicates a revenue of HK$2,063 million for the period, reflecting a 2.8% decrease compared to the previous year. Despite this, profitability saw significant growth, with EBITDA rising 18.8% to HK$248 million and a net profit of HK$40.3 million. The EBITDA margin improved to 12.0%, up by 2.2 percentage points year-on-year, showcasing enhanced operational efficiency.

Some other highlights:

Net profit margin improved to 2.0% from 1.0% YoY.

Medical Services: HK$1,264,266,000 (61.3% of total, down 3.7% YoY) .

Aesthetic Medical, Beauty and Wellness: HK$629,762,000 (30.5% of total, down 5.4% YoY) .

Veterinary and Other Services: HK$168,869,000 (8.2% of total, up 18.9% YoY) .

The "Management Discussion and Analysis" section attributes the overall revenue decline to macroeconomic challenges and weakened consumption in Hong Kong and Mainland China, with varying impacts across segments. The Veterinary and Other Services segment saw growth, offsetting some declines in medical and aesthetic services.

「注：本人倪国权为证监会持牌人士。截至本评论文章发表日止，本人及/或其有联系者并无持有全部提及之证券的所有相关财务权益。」; Or
” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “